Chronic Disease Management Mitigates the Relationship between Literacy and Health Outcomes Darren A. DeWalt, MD, MPH RWJ Clinical Scholars Program Division.

Slides:



Advertisements
Similar presentations
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Advertisements

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
ETIM-1 CSE 5810 CSE5810: Intro to Biomedical Informatics Mobile Computing to Impact Patient Health and Data Exchange and Statistical Analysis Presenter:
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Improved Treatment of Ischemic Heart Disease and Disability and Death in the Elderly Kate Stewart Mary Beth Landrum David Cutler Academy Health June 27,
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.
Virtually Possible: The Use of Technology in the Treatment Of Diabetes Cheryl B. Masters, PhD, Jerry Nymberg, MD, Mark Robinson, MD, Andrea Cochran, PhD,
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Monthly Journal article review: Vimmi Kang PGY 2
Differences in the Quality of the Patient- Physician Relationship Among Terminally Ill African American and White Patients: Impact on Advance Care Planning.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Outpatient Center. West Baltimore Chronic Disease Profile and Acute Care Utilization.
R 63 year old widowed, bible carrying, male truck driver A1c = 9.9% (goal
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Literacy, Knowledge, Health Beliefs, and Self-efficacy among Urban, Low-income, Obese African American Women Feleta L. Wilson, PhD, RN 1 May T. Dobal,
Evaluating the Newest Vital Sign: A More Convenient Measure of Health Literacy Lindsey McCormick, MS3 William Curry, MD, MS Penn State College of Medicine.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Presenter Disclosures (1)The following personal financial relationships with commercial interests relevant to this presentation existed during the past.
Management of Hypertension according to JNC 7
Disability After Traumatic Brain Injury among Hispanic Children
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
University of North Carolina-Chapel Hill Department of Medicine
Nephrology Journal Club The SPRINT Trial Parker Gregg
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
The SPRINT Research Group
Estephanie Olivares, HHSD Program Coordinator
Cheryl Schraeder, RN, PhD, FAAN Health Systems Research Center
Darren DeWalt, MD, MPH & Michael Pignone, MD, MPH
Presented at the American Diabetes Association
Disparities in process and outcome measures among adults with persistent asthma David M. Mosen, PhD, MPH; Michael Schatz, MD, MS; Rachel Gold, PhD; Winston.
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
THE RELATIONSHIP BETWEEN SOCIAL SUPPORT, ACES, AND CHRONIC PAIN
Health and Human Services National Heart, Lung, and Blood Institute
Sunil Kripalani, MD, MSc;1 Christianne L
Lisa Weiss, M.D. Brian F. Pendleton, Ph.D. Susan Labuda Schrop, M.S.
Veterans with life-limiting illness: Baseline descriptors
A Growth Curve Analysis Participant Baseline Characteristics
Evidence of a Program's Effectiveness in Improving Colorectal Cancer Screening Rates in Federally Qualified Health Centers Robert L. Stephens, PhD, MPH1;
Sometimes it’s a knock on the door that can make all the difference.
Don’t Nudge Me: The Limits of Behavioral Economics in Medicine
Polypharmacy In Adults: Small Test of Change
EMPHASIS-HF Extended Follow-up
Nursing-Sensitive Quality Indicators And Safety Initiatives
Management of Type II Diabetes
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Hemoglobin A1c Targets for Glycemic Controls
The Hypertension in the Very Elderly Trial (HYVET)
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Monthly Journal article review: Vimmi Kang PGY 2
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Risk Stratification for Care Management
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Chronic Disease Management Mitigates the Relationship between Literacy and Health Outcomes Darren A. DeWalt, MD, MPH RWJ Clinical Scholars Program Division of General Internal Medicine University of North Carolina, Chapel Hill June 7, 2004

Collaborators Michael Pignone, MD, MPH Russell Rothman, MD, MPP Robert Malone, PharmD Morris Weinberger, PhD RWJ Clinical Scholars Program Pfizer Health Literacy Initiative UNC Program on Health Outcomes UNC Center for Research on Chronic Illness Funding Sources

Low Literacy Related to Worse Control of Chronic Illness Diabetes –Worse glycemic control –More long-term sequelae HIV –Higher viral load Depression –More severe disease Hospitalization –Consequence of several diseases

LiteracyHealth understanding/ knowledge Health behavior/ Self-care Health outcome Educational opportunity (sum of general knowledge) Learning potential Exposure to reading Poverty/wealth/SES Poor environment Conceptual Framework Patient-provider communication Self-efficacy Participation in medical encounter Trust in physician/health system

Chronic Disease Management

Disease Management Components Multidisciplinary teams/Care coordination Defined follow-up procedures Treatment algorithms based on best available evidence Information systems for tracking patients Patient education for self-care

Disease Management May Reduce Literacy-related Barriers Careful design of educational strategies may improve self-care, particularly for low literacy patients Disease management programs have not examined the role of literacy in the effectiveness of the interventions

Literacy Health-related knowledge Self-efficacy/ health behavior Access to providers/therapy Quality of care Health Outcome Learning potential Educational opportunity SES Why Would Disease Management Work?

Evidence of Effectiveness Heart failure randomized clinical trial Diabetes randomized clinical trial

Disease Management Intervention 1-hour individualized education session Education booklet < 6th grade level Digital bathroom scale Scheduled follow-up phone calls Easy access to our team

Randomized Controlled Trial

Design of RCT Usual Care Disease Management compared to Included patients with low and high literacy for a pre-specified sub-group analysis 64 patients65 patients

Outcome Measures Primary Outcomes –HF-quality of life (Minnesota Living with Heart Failure Questionnaire) –Hospitalization or death Secondary Outcomes –HF knowledge –HF specific self-efficacy –HF self-care behavior

Follow-up to Date Enrolled and randomized 129 Control 65 Intervention 64 Withdrawal: 2 58 (95%)56 (95%) Withdrawal: 6 50 (85%)56 (93%) 6 month to date 12 month to date Death: 5

Baseline Characteristics Variable Control (n=65) Intervention (n=64) Mean Age, years (SD)62 (10)63 (10) African American, %55%56% Male, %42%58% Education, years Income <15,000/yr, %68%69% Medicaid, %32%36% Medicare, %73%72% Literacy (S-TOFHLA) Inadequate, %40%45%

Baseline HF Characteristics Variable Control (n=65) Intervention (n=64) Time with HF, median years (interquartile range) 3 (1-9)2.5 (1-8) NYHA class, % II III IV Systolic dysfunction, %4836 Medications, % ACEI or ARB6975  -blocker 7155 Digoxin3727

Reduced Hospital Admission or Death Incidence Rate Unadjusted Incidence Rate Ratio (IRR) 0.66 [0.38, 1.12] Adjusted IRR 0.56 [0.32, 0.95] *Adjusted for baseline HFQOL, B-blocker use, digoxin use, systolic dysfunction and hypertension

Results for Patients with Low Literacy 53 patients found to have inadequate literacy based on the TOFHLA (28 intervention, 25 control)

Inadequate Literacy Lower Admission or Death Incidence Rate Unadjusted Incidence Rate Ratio (IRR) 0.69 [0.28, 1.75] Adjusted* IRR 0.38 [0.16, 0.88] *Adjusted for baseline HFQOL, B-blocker use, ACEI or ARB use, and hypertension

Heart Failure Study Summary HF disease management appears to decrease the combined endpoint of hospitalization or death Effect may be greater among those with low literacy

Diabetes Disease Management

Patient registry Treatment and monitoring algorithms Patient education Care coordination

Educational Strategies Patient centered learning Focus on behaviors rather than knowledge Repetition/reinforcement Teach-back method

Care Coordination Call patient at least once a month Review self-care skills Help to navigate health care system Address barriers of medication access, transportation, and communication

Evaluation with RCT Usual Care Disease Management compared to 112 patients 105 patients One Time Management Session

Outcome Measures Primary Measures –A1C –Blood pressure –Aspirin use Secondary Measures –Diabetes knowledge –Treatment satisfaction –Medical visits –Potential harms

Variable Control (n=105) Intervention (n=112) Age, mean (SD), y56.7 (10.8)53.5 (12.5) Female, No. (%)59 (56%)63 (56%) African American, No. (%)62 (59%)78 (70%) Household Income  $20,000, No. (%) 78 (76%)77 (69%) Less than HS education, No. (%)46 (44%)40 (36%) REALM Score, median (IQR)57 (32-64)55 (31-62) Low Literacy, No. (%)**34 (32%)49 (44%) Demographics ** Defined as  6th Grade Literacy Level on REALM

Improvement in A1C Worse Control Better Control

Results According to Literacy Status

Diabetes Control: Results for Patients with Literacy Above 6th Grade Level Worse Control Better Control

Diabetes Control: Results for Patients with Literacy at or Below 6 th Grade Level Worse Control Better Control

Diabetes Study Summary Patients with low literacy had greater improvement in glycemic control

Comment Both studies performed in general internal medicine practice at academic center Both studies used multiple components in the intervention to improve outcomes Cannot isolate individual effects of parts of the interventions

Conclusions Chronic disease management appears to mitigate literacy related disparities Structured care appears helpful, especially for patients with low literacy Easy-to-read materials insufficient Need to combine with other systems of care to address other barriers

Future Directions Research on the components of disease management that are critical for patients with low literacy Research on existing disease management programs and whether they reduce disparities Consider disease management as a policy strategy to reduce disparities

Baseline HF Measures Variable Control (n=65) Intervention (n=64) Knowledge, mean percent5756 Self-efficacy, mean score22 Daily weight measurement, %1513 HFQOL score, mean score (range 0-105) 5745

Improved HF Knowledge, Self-Efficacy, and Self-Care Behavior 6 Month OutcomeControlIntervention Difference (CI) P value Knowledge change (4, 19) <0.01 Self-efficacy change (0.5, 3.1) <0.01 Daily weight measurement, % (53, 81) <0.01

No Difference in HFQOL at 6 or 12 Months Time Unadjusted Difference (CI) Unadjusted P value Adjusted Difference* (CI) Adjusted P value 6 Months-6 (-15, 2) (-11, 6) Months -3 (-11, 5) 0.47 (-9, 7) 0.84 *Adjusted for baseline HFQOL, B-blocker use, systolic function, sex, diabetes, hypertension

Follow-up to Date Enrolled and randomized 129 Control 65 Intervention 64 Withdrawal: 2 58 (95%)56 (95%) Withdrawal: 6 50 (85%)56 (93%) 6 month to date 12 month to date Death: 5